Supply Chain Intelligence

Lantheus Holdings, Inc. Supply Chain

LNTH supply chain intelligence for Lantheus Holdings, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

LNTH ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

16Suppliers
26Customers
1Debt Items
20Related Chains

Lantheus Holdings, Inc. Suppliers

TickerNameConfidenceEvidence
PMF-NETWORKS PMF-NETWORKS 92% Our agreements with our PMF networks allow for termination upon the occurrence of specified events, including material breach or bankruptcy by either party
POINT POINT 92% we are also currently dependent on POINT to develop commercial product capacity and manufacture for both PNT2003 and PNT2002
ACIU AC Immune SA 72% Reciprocal relationship from ACIU graph: Reciprocal relationship from LNTH graph: Item 1A. “Risk Factors” of this Form 10-K for information regarding certain risks associated with our raw materials a…
ACIU AC Immune SA 72% Item 1A. “Risk Factors” of this Form 10-K for information regarding certain risks associated with our raw materials and supply arrangements. Manufacturing The commercial manufacture of PYLARIFY and N…
CATX Perspective Therapeutics, Inc. 72% tion and the potential that efforts to extend or secure separate or otherwise adequate payment for radiopharmaceutical diagnostics are unsuccessful. • The extensive government regulation and oversigh…
CATX Perspective Therapeutics, Inc. 72% Reciprocal relationship from CATX graph: Reciprocal relationship from LNTH graph: Reciprocal relationship from CATX graph: Reciprocal relationship from LNTH graph: Reciprocal relationship from CATX g…
NVSEF Novartis AG 72% Reciprocal relationship from NVSEF graph: Reciprocal relationship from LNTH graph: ources, raw materials and, for our diagnostic imaging agents, staff at imaging centers and hospitals and PET scanner…
NVSEF Novartis AG 72% ources, raw materials and, for our diagnostic imaging agents, staff at imaging centers and hospitals and PET scanner capacity. For example, for PNT2003, our principal competitors may include Novartis…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from LNTH graph: g degrees of governmental regulation in the countries in which we or our partners operate, and the general trend is …
ORANY ORANY 72% g degrees of governmental regulation in the countries in which we or our partners operate, and the general trend is toward increasingly stringent regulation. To assess and facilitate compliance with …
RADX Radiopharm Theranostics Limited 72% Reciprocal relationship from RADX graph: Reciprocal relationship from LNTH graph: tion and the potential that efforts to extend or secure separate or otherwise adequate payment for radiopharmaceutica…
RADX Radiopharm Theranostics Limited 72% tion and the potential that efforts to extend or secure separate or otherwise adequate payment for radiopharmaceutical diagnostics are unsuccessful. • The extensive government regulation and oversigh…
REGN Regeneron Pharmaceuticals, Inc. 72% Reciprocal relationship from REGN graph: Reciprocal relationship from LNTH graph: Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Comparison of the Pe…
REGN Regeneron Pharmaceuticals, Inc. 72% Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Comparison of the Periods Ended December 31, 2025 and 2024 - Revenues” for further information on reve…
TLX Telix Pharmaceuticals Limited 72% Reciprocal relationship from TLX graph: Reciprocal relationship from LNTH graph: Reciprocal relationship from TLX graph: Reciprocal relationship from LNTH graph: ial financial, manufacturing, sales a…
TLX Telix Pharmaceuticals Limited 72% ial financial, manufacturing, sales and marketing, distribution and other resources. • For PYLARIFY, our principal competitors are currently Telix Pharmaceuticals Limited, Blue Earth Diagnostics Ltd.…

Lantheus Holdings, Inc. Customers

TickerNameConfidenceEvidence
ACIU AC Immune SA 72% Reciprocal relationship from ACIU graph: Reciprocal relationship from LNTH graph: Reciprocal relationship from ACIU graph: Reciprocal relationship from LNTH graph: Reciprocal relationship from ACIU g…
ACIU AC Immune SA 72% Item 1A. “Risk Factors” of this Form 10-K for information regarding certain risks associated with our raw materials and supply arrangements. Manufacturing The commercial manufacture of PYLARIFY and N…
CATX Perspective Therapeutics, Inc. 72% ble for the performance of certain key tasks or functions, for example related to manufacturing or regulatory strategy, or where decisions may be controlled by, or subject to the approval of our coll…
CATX Perspective Therapeutics, Inc. 72% Reciprocal relationship from CATX graph: Reciprocal relationship from LNTH graph: ble for the performance of certain key tasks or functions, for example related to manufacturing or regulatory strateg…
MNPR Monopar Therapeutics Inc. 72% Reciprocal relationship from MNPR graph: ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities …
NVSEF Novartis AG 72% Reciprocal relationship from NVSEF graph: Reciprocal relationship from LNTH graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from LNTH graph: Reciprocal relationship from NVSE…
NVSEF Novartis AG 72% ncreasingly competitive environment in which other PSMA PET imaging agents have been approved, for which discounts related to those other agents have been offered to customers and for which TPT Statu…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from LNTH graph: hod-of-use patents listed in the FDA’s publication, ”Approved Drug Products with Therapeutic Equivalence Evaluations…
ORANY ORANY 72% hod-of-use patents listed in the FDA’s publication, ”Approved Drug Products with Therapeutic Equivalence Evaluations” (the “Orange Book”), as well as additional manufacturing patents that are not Ora…
RADX Radiopharm Theranostics Limited 72% ble for the performance of certain key tasks or functions, for example related to manufacturing or regulatory strategy, or where decisions may be controlled by, or subject to the approval of our coll…
RADX Radiopharm Theranostics Limited 72% Reciprocal relationship from RADX graph: Reciprocal relationship from LNTH graph: Reciprocal relationship from RADX graph: Reciprocal relationship from LNTH graph: ble for the performance of certain …
REGN Regeneron Pharmaceuticals, Inc. 72% Reciprocal relationship from REGN graph: Reciprocal relationship from LNTH graph: Reciprocal relationship from REGN graph: Reciprocal relationship from LNTH graph: Reciprocal relationship from REGN g…
REGN Regeneron Pharmaceuticals, Inc. 72% Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Comparison of the Periods Ended December 31, 2025 and 2024 - Revenues” for further information on reve…
TLX Telix Pharmaceuticals Limited 72% Reciprocal relationship from TLX graph: Reciprocal relationship from LNTH graph: ncreasingly competitive environment in which other PSMA PET imaging agents have been approved, for which discounts rel…
TLX Telix Pharmaceuticals Limited 72% ncreasingly competitive environment in which other PSMA PET imaging agents have been approved, for which discounts related to those other agents have been offered to customers and for which TPT Statu…
ACP-LANTERN-CO-INVEST-LLC ACP-LANTERN-CO-INVEST-LLC 62% RG and the Lantheus Veterans, Employees and Reservists Inspired to Act and Serve ERG. We are committed to promoting a culture of ethics and compliance. Our Code of Conduct and Ethics reflects our com…
BLUE-EARTH-DIAGNOSTICS-LTD BLUE-EARTH-DIAGNOSTICS-LTD 62% mote PYLARIFY to customers, to clinically and commercially differentiate PYLARIFY from other products on the market and to maintain PYLARIFY as the most utilized PSMA PET imaging agent in a competiti…
BRACCO-DIAGNOSTICS-INC BRACCO-DIAGNOSTICS-INC 62% that we serve. Any delay or inability to enter into these arrangements, including our ability to negotiate favorable financial terms in these agreements, or if, despite favorable financial terms, the…
CERVEAU-TECHNOLOGIES-INC CERVEAU-TECHNOLOGIES-INC 62% ailability of PET scanners could impact our ability to grow PYLARIFY and to successfully launch and commercialize radiodiagnostic products in our pipeline. Use of our radiopharmaceutical diagnostic p…
LIFE-MOLECULAR-IMAGING-LTD LIFE-MOLECULAR-IMAGING-LTD 62% ailability of PET scanners could impact our ability to grow PYLARIFY and to successfully launch and commercialize radiodiagnostic products in our pipeline. Use of our radiopharmaceutical diagnostic p…
MEILLEUR-TECHNOLOGIES-INC MEILLEUR-TECHNOLOGIES-INC 62% ailability of PET scanners could impact our ability to grow PYLARIFY and to successfully launch and commercialize radiodiagnostic products in our pipeline. Use of our radiopharmaceutical diagnostic p…
NEW-ENGLAND-NUCLEAR-CORPORATION NEW-ENGLAND-NUCLEAR-CORPORATION 62% RG and the Lantheus Veterans, Employees and Reservists Inspired to Act and Serve ERG. We are committed to promoting a culture of ethics and compliance. Our Code of Conduct and Ethics reflects our com…
NORIA-THERAPEUTICS-INC NORIA-THERAPEUTICS-INC 62% Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Comparison of the Periods Ended December 31, 2024 and 2023 - Revenues” for further information on reve…
RATIO-THERAPEUTICS-LLC RATIO-THERAPEUTICS-LLC 62% Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Comparison of the Periods Ended December 31, 2024 and 2023 - Revenues” for further information on reve…
SIMILARLY-INSIGHTEC-LTD SIMILARLY-INSIGHTEC-LTD 62% Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Comparison of the Periods Ended December 31, 2024 and 2023 - Revenues” for further information on reve…
TELIX-PHARMACEUTICALS-LIMITED-NOVARTIS-AG TELIX-PHARMACEUTICALS-LIMITED-NOVARTIS-AG 62% sh and distribute these products on a just-in-time basis, because the underlying radioisotope is in a constant state of decay. For example, the radioisotope used in PYLARIFY is F-18, which has a 110 …

Lantheus Holdings, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
LNTH-DEBT Debt stack $625.8M 90% Market cache reports total debt of $625.8M.

Lantheus Holdings, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Lantheus Holdings, Inc..

Lantheus Holdings, Inc. Ownership

HolderNameConfidenceEvidence
LNTH-OWNER-JANUS-HENDERSON-GROUP-PLC JANUS HENDERSON GROUP PLC 90% 13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 411 tracked holders.

Lantheus Holdings, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CLRB Cellectar Biosciences, Inc. 100.00 2
ACET Adicet Bio, Inc. 100.00 2
ORANY ORANGE 100.00 1 ['customer', 'supplier']
SDGR Schrödinger, Inc. 100.00 2
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
ABT Abbott Laboratories 100.00 2
EDSA Edesa Biotech, Inc. 100.00 2
ATNM Actinium Pharmaceuticals, Inc. 100.00 2
CATX Perspective Therapeutics, Inc. 100.00 1 ['customer', 'supplier']
SLGL Sol-Gel Technologies Ltd. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
CPMV Mosaic ImmunoEngineering, Inc. 100.00 2
ELVN Enliven Therapeutics, Inc. 100.00 2
BNBX BNB Plus Corp. 100.00 2
BSX Boston Scientific Corporation 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
ARTV Artiva Biotherapeutics, Inc. 100.00 2
View LNTH supply chain intel →

Explore the full interactive supply chain map for Lantheus Holdings, Inc..

Open LNTH supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map